Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03579160 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03579160 is a Phase 2 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 10 participants.
The verdict
NCT03579160, a Phase 2 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The use of topical beta-blockers, such as 0.25% timolol, in promoting wound healing is currently emerging in the academic literature. The investigators will enroll 82 patients who have their skin cancer surgically removed resulting in the need of a full-thickness skin graft. The objective of this randomized safety study is to determine the safety and efficacy of 0.25% timolol in promoting wound healing in full-thickness skin grafts compared to standard of care.
Interventions
- OTHER Vaseline dressing
- DRUG 0.25% timolol gel with full-thickness skin grafts
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-01-02 |
| Est. Completion | 2022-01-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03579160
The ClinicalTrials.gov registry entry for NCT03579160 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vaseline dressing is the first listed.
NCT03579160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03579160 about?
NCT03579160 is a clinical study titled "Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes". The use of topical beta-blockers, such as 0.25% timolol, in promoting wound healing is currently emerging in the academic literature. The investigators will enroll 82 patients who have their skin cancer surgically removed resulting in the need of a full-thickness skin graft. The objective of this ra...
What is the current status of trial NCT03579160?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2019-01-02. Estimated completion is 2022-01-10.
What interventions are being tested in trial NCT03579160?
The interventions under investigation include: Vaseline dressing (OTHER), 0.25% timolol gel with full-thickness skin grafts (DRUG).
Who is sponsoring clinical trial NCT03579160?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.